Cyclooxygenase 2 - Implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives

Gut

Volumn 49, Issue 3, 2001, Pages 443-453

  Halter, F ^a   Tarnawski, A S ^a   Schmassmann, A ^b   Peskar, B M ^c  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENE) 2 METHOXYIMINO 4 THIAZOLONE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBROBLAST GROWTH FACTOR; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN; ROFECOXIB;

COLITIS; DIGESTIVE SYSTEM ULCER; DYSPEPSIA; ENZYME REPRESSION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMAN; INTESTINE PERFORATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA; STOMACH ULCER; ULCER HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; WOUND HEALING;

EID: 0034864294     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.3.443     Document Type: Review

References (156)

1. Update on aspirin in the treatment and prevention of cardiovascular disease
2. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
3. Risk of Alzheimer's disease and duration of NSAID use
4. Non-steroidal anti-inflammatory drugs and peptic ulcers
5. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
6. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
7. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study
8. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs
9. The advent of highly selective inhibitors of cyclooxygenase - A review
10. Gastric adaptation. Studies in humans during continuous aspirin administration
11. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol
12. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: Predisposition to ulceration and relation to Helicobacter pylori
13. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial
14. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs
15. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
16. Upper gastrointestinal lesions in elderly patients presenting for endoscopy: Relevance of NSAID usage
17. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions
18. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
19. Nonsteroidal antirheumatic drugs and acetylsalicylic acid: Adverse effects distal to the duodenum
20. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs
21. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
22. Enhanced gastric leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs
23. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSAIDs
24. Focal gastric mucosal blood flow in aspirin-induced ulceration
25. Indomethacin-induced leukocyte adhesion in mesenteric venules: Role of lipoxygenase products
26. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate
27. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury
28. Role of oxygen-derived free radicals in indomethacin-induced gastric injury
29. Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats
30. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process
31. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
32. Absorption of drugs from the stomach. II. The human
33. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat
34. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity
35. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity
36. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury
37. Effect of naproxen (NAP) on gastric mucosal hydrophobicity
38. The hydrophobic barrier properties of gastrointestinal mucus
39. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH
40. Review article: New insights into prostaglandins and mucosal defence
41. Nitric oxide: An endogenous modulator of leukocyte adhesion
42. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit
43. Influence of prostaglandins, omeprazole, and indomethacin on healing of experimental gastric ulcers in the rat
44. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: Interaction with indomethacin
45. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs
46. Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin
47. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers
48. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing
49. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells
50. Gastric microvascular endothelium: A major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat
51. Effect of indomethacin on gastric mucosal blood flow around acetic acid-induced gastric ulcers in rats
52. Prostaglandins for peptic ulcer: A promise unfulfilled
53. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCL, NaOH, hypertonic NaCl, and thermal injury
54. Prostaglandin protection of human isolated gastric glands against indomethacin and ethanol injury. Evidence for direct cellular action of prostaglandin
55. Cytoprotection and healing: Two unequal brethren
56. Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: Effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor
57. NSAID-induced mucosal injury: Analysis of gastric toxicity of new generation NSAIDs: Ulcerogenicity compared with ulcer healing
58. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat
59. A nitric oxide-releasing nonsteroidial anti-inflammatory drug accelerates gastric ulcer healing in rats
60. Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen
61. Endogenous nitric oxide and sensory neuropeptides interact in the modulation of the rat gastric microcirculation
62. Endogenous nitric oxide as a mediator of gastric mucosal vasodilatation during acid secretion
63. Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide
64. Nitric oxide donor decreases neutrophil adhesion in both lung and peritoneum during peritonitis
65. Nitric oxide donors increase mucus gel thickness in rat stomach
66. Nitric oxide modulates epithelial permeability in the feline small intestine
67. NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects
68. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
69. Towards a better aspirin
70. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases
71. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
72. Induction of cyclooxygenase 1 and 2 in rat stomach during endotoxemia: Role in resistance to damage
73. COX-2 inhibitors
74. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-infammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
75. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats
76. Rofecoxib (Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
77. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
78. Celecoxib versus diclofenac in a long-term management of rheumatoid arthritis: Randomized double-blind comparison
79. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
80. Comparison of the rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
81. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
82. 2) synthesis in healthy humans
83. COX-2 selectivity and lack of gastrointestinal toxicity: True, true and unrelated?
84. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
85. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
86. Expression of mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
87. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX
88. Cyclooxygenase-2 as a therapeutic target
89. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
90. Effects of non-steroidal antiinflammatory drugs on prostaglandin H synthase isoenzyme 2 (cyclooxygenase 2) production by porcine gastric mucosa in organ culture
91. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach
92. Characterisation of prostaglandin G/H synthetase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
93. Expression of cyclooxygenase-1 and -2 (COX-1 and COX-2) in normal gastric mucosa. Effect of antacid (hydrotalcit) treatment
94. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
95. Expression and localization of cyclooxygenase-2 in normal and ulcerated human gastric mucosa, and in cultured human endothelial cells
96. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats
97. Immunohistochemical distribution of constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) in benign and malignant gastric mucosa
98. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa
99. Levels of cyclooxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats
100. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats
101. Cylooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa
102. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach
103. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis
104. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection
105. Helicobacter pylori infection induces cyclooxyygenase-2 expression in human gastric mucosa
106. Expression of the cyclooxygenase-2 gene in gastric epithelium
107. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro
108. Induction of cyclooxygenase-2 in rat gastric epithelial cell line by epiregulin and basic fibroblast growth factor
109. HGF triggers activation of COX-2 gene in rat gastric epithelial cells: Action mediated through ERK2 signaling pathway
110. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge
111. Is intestinal toxicity of nonsteroidal anti-inflammatory drugs accounted for by cyclooxygenase-1 inhibition?
112. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans
113. Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection
114. Oxidation and genotoxicity of fecapentaene-12 are potentiated by prostaglandin H synthase
115. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
116. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
117. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
118. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
119. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
120. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
121. Evidence of weakening of gastric mucus integrity by Campylobacter pylori
122. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - Influence of age, smoking, ulceration and Helicobacter pylori
123. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers
124. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
125. Helicobacter pylori infection and chronic gastric acid hyposecretion
126. Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis
127. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent ulcers
128. Helicobacter pylori, NSAIDs, and peptic ulcers
129. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
130. H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID)-induced gastroduodenal ulceration
131. No evidence of H. pylori-NSAID interaction in ulcer formation: Results of double-blind, placebo-controlled trials
132. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
133. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
134. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
135. Omeprazole: Helicobacter pylori makes thee greater yet
136. Influence of H. pylori (HP) infection and/or low dose aspirin (AASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs
137. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: Role of cyclooxygenase-2
138. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
139. Selective COX-2 inhibitors aggravate ischemia-reperfusion injury in the rat stomach
140. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: Consequences for nonsteroidal antiinflammatory drug efficacy
141. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
142. Effects of novel antiinflammatory compounds on healing of acetic acid-induced gastric ulcer in rats
143. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
144. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
145. Cyclooxygenase-2 dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen
146. Regulation of gastric mucosal integrity, by endogenous nitric oxide: Interactions with prostanoids and sensory neuropeptides in the rat
147. Cyclooxygenase-2 derived prostaglandins interact with nitric oxide and afferent neurons in the maintenance of rat gastric mucosal integrity
148. Prostaglandin synthase 1-gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
149. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
150. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells
151. Celecoxib approved as NSAID with some concessions on class warning
152. Vioxx study dose and interactions may hinder RA future indication
153. Several death show a link to celebrex
154. Gastropathy due to celexoxib, a cyclooxygenase-2 inhibitor
155. COX-2 selective NSAIDs: Biology, promises, and concerns